Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansoh Pharmaceutical Group CoHKSE:03692 -1.51%92 Piotroski F-Score is 6 as of Jul. 21, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates HKSE:03692 with a GF Score™ of 92/100 and a GF Value™ of HK$26.67 (Modestly Overvalued). Among 979 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 78.96% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Hansoh Pharmaceutical Group Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:
HKSE:03692'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 8
Current: 6
During the past 10 years, the highest Piotroski F-Score of Hansoh Pharmaceutical Group Co was 8. The lowest was 3. And the median was 5.
Hansoh Pharmaceutical Group Co (HKSE:03692) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Hansoh Pharmaceutical Group Co Piotroski F-Score Related Terms
Hansoh Pharmaceutical Group Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Piotroski F-Score Chart
HKSE:03692 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Hansoh Pharmaceutical Group Co's current Net Income (TTM) was 6,137.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Hansoh Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 7,444.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Hansoh Pharmaceutical Group Co's return on assets of this year was 0.18157457. Hansoh Pharmaceutical Group Co's return on assets of last year was 0.12916449.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Hansoh Pharmaceutical Group Co's gearing of this year was 0.00135109. Hansoh Pharmaceutical Group Co's gearing of last year was 0.00186286.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Hansoh Pharmaceutical Group Co's current ratio of this year was 8.09007426. Hansoh Pharmaceutical Group Co's current ratio of last year was 10.18166054.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Hansoh Pharmaceutical Group Co's number of shares in issue this year was 5980.697. Hansoh Pharmaceutical Group Co's number of shares in issue last year was 5949.989.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Hansoh Pharmaceutical Group Co's gross margin of this year was 0.90033042. Hansoh Pharmaceutical Group Co's gross margin of last year was 0.90984215.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Hansoh Pharmaceutical Group Co's asset turnover of this year was 0.49118545. Hansoh Pharmaceutical Group Co's asset turnover of last year was 0.36224277.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
0
+
0
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Hansoh Pharmaceutical Group Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Hansoh Pharmaceutical Group Co (HKSE:03692) has a Piotroski F-Score of 6 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Hansoh Pharmaceutical Group Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #206 out of 979 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Hansoh Pharmaceutical Group Co's Piotroski F-Score too high?
Hansoh Pharmaceutical Group Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Hansoh Pharmaceutical Group Co's value of 6 is 20% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #206 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #206 out of 979 companies for Piotroski F-Score. This places Hansoh Pharmaceutical Group Co in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Hansoh Pharmaceutical Group Co's value of 6 is 20% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HKSE:03692) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$26.67, compared to a current price of HK$32.56 — trading 22.1% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Drug Manufacturers industry median of 5.00. Hansoh Pharmaceutical Group Co's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HKSE:03692), the current Piotroski F-Score is 6 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HKSE:03692) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of HK$32.56 is trading 22.1% above its estimated GF Value™ of HK$26.67.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HKSE:03692:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: HK$26.67 vs. price of HK$32.56 (22.1% above fair value)
Industry Position: 20% above the Drug Manufacturers median (#206 of 979)
No single metric tells the full story. See the HKSE:03692 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
92GF Score
Get the complete analysis for HKSE:03692
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03692 has been successfully added to your 
